Our top pick for
OncoCyte Corporation is a biotechnology business based in the US. OncoCyte Corporation shares (OCX) are listed on the NYSE MKT and all prices are listed in US Dollars. OncoCyte Corporation employs 33 staff and has a trailing 12-month revenue of around USD$713,000.
|Latest market close||USD$2.39|
|52-week range||USD$1.15 - USD$3.51|
|50-day moving average||USD$2.0276|
|200-day moving average||USD$1.7323|
|Wall St. target price||USD$4.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.372|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-20.33%|
|1 month (2020-12-15)||-5.53%|
|3 months (2020-10-15)||45.73%|
|6 months (2020-07-15)||86.72%|
|1 year (2020-01-15)||-17.01%|
|2 years (2019-01-15)||57.24%|
|3 years (2018-01-15)||N/A|
|5 years (2016-01-15)||3.51|
|Gross profit TTM||USD$0|
|Return on assets TTM||-42.97%|
|Return on equity TTM||-98.72%|
|Market capitalisation||USD$155.7 million|
TTM: trailing 12 months
There are currently 2.2 million OncoCyte Corporation shares held short by investors – that's known as OncoCyte Corporation's "short interest". This figure is 7.7% down from 2.4 million last month.
There are a few different ways that this level of interest in shorting OncoCyte Corporation shares can be evaluated.
OncoCyte Corporation's "short interest ratio" (SIR) is the quantity of OncoCyte Corporation shares currently shorted divided by the average quantity of OncoCyte Corporation shares traded daily (recently around 3.7 million). OncoCyte Corporation's SIR currently stands at 0.6. In other words for every 100,000 OncoCyte Corporation shares traded daily on the market, roughly 600 shares are currently held short.
However OncoCyte Corporation's short interest can also be evaluated against the total number of OncoCyte Corporation shares, or, against the total number of tradable OncoCyte Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case OncoCyte Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 OncoCyte Corporation shares in existence, roughly 30 shares are currently held short) or 0.0429% of the tradable shares (for every 100,000 tradable OncoCyte Corporation shares, roughly 43 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against OncoCyte Corporation.
Find out more about how you can short OncoCyte Corporation stock.
We're not expecting OncoCyte Corporation to pay a dividend over the next 12 months.
Over the last 12 months, OncoCyte Corporation's shares have ranged in value from as little as $1.15 up to $3.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while OncoCyte Corporation's is 2.3108. This would suggest that OncoCyte Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.
OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.